Beclometasone dipropionate 是 Beclometasone 的前体药物,是口服有效的糖皮质激素受体激动剂。Beclometasone dipropionate 通过糖皮质激素受体发挥作用,抑制炎症和过度增殖。Beclometasone dipropionate 可用于哮喘研究。
生物活性 | Beclometasone dipropionate, the prodrug of Beclometasone, is an orally active and potentglucocorticoid recepteragonist. Beclometasone dipropionate acts via aglucocorticoid receptorand suppresses inflammation and hyperproliferation. Beclometasone dipropionate can be used for asthma[1][2]. |
IC50& Target | |
体外研究 (In Vitro) | Beclometasone dipropionate (1-100 nM; 20 min) inhibits STAT-1 expression and reduces the levels of iNOS, ROS and NT generated by rhIL-17A in 16HBE cells[2].
Western Blot Analysis[2] Cell Line: | 16HBE cells | Concentration: | 1, 10 and 100 nM | Incubation Time: | 20 min | Result: | Reduced the levels of iNOS, ROS and NT generated by rhIL-17A. |
|
体内研究 (In Vivo) | Beclometasone dipropionate (150 μg/kg; nebulization; male BALB/c mice) relieves asthma and decreases total cell number and relative eosinophil number[1].
Animal Model: | Ten-week-old male Balb/c mice[2]. | Dosage: | 5 mg/kg (100 μg/ml for 60 min). | Administration: | Orally at 24 h and 1 h before the LPS aerosol. | Result: | Significantly (P< 0.05) inhibited the decrease of IL-10 level in BAL fluid induced by LPS exposure. Markedly reduced the release of both MMP-2 and MMP-9.
|
Animal Model: | Male BALB/c mice with asthma[1] | Dosage: | 150 μg/kg | Administration: | Nebulization | Result: | Decreased total cell number and relative eosinophil number in BALF. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(191.92 mM) H2O :< 0.1 mg/mL (ultrasonic)(insoluble) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 1.9192 mL | 9.5962 mL | 19.1924 mL | 5 mM | 0.3838 mL | 1.9192 mL | 3.8385 mL | 10 mM | 0.1919 mL | 0.9596 mL | 1.9192 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.80 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (4.80 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|